Cytisinicline for Smoking Cessation
JAMA Internal Medicine · 01.06.2025 · 185 (6) · 648
DOI: 10.1001/jamainternmed.2025.0628 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.06.2025. Verfasst von Nancy A Rigotti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hosp…. Hauptthemen laut MEDLINE: Smoking Cessation, Benzazepines, Nicotinic Agonists, Smoking Cessation Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance New smoking cessation medication options are needed. Cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, has demonstrated smoking cessation efficacy in 1 US trial. Additional evidence is needed.
Objective
To reproduce the findings of the efficacy and tolerability of cytisinicline compared with placebo for smoking cessation and to test its effect on nicotine craving as a mechanism of action. Design, Settings, and Participants This was a 3-group double-blind, placebo-controlled phase 3 replication randomized clinical trial (ORCA-3) conducted at 20 clinical trial sites in the US from January 2022 to March 2023. It compared 6 and 12 weeks of a novel cytisinicline regimen to placebo among adults who smoked 10 or more cigarettes daily and sought to quit. Participants were randomized (1:1:1) to 3-mg cytisinicline 3 times daily for 12 weeks; 3-mg cytisinicline 3 times daily for 6 weeks followed by placebo for 6 weeks; or placebo 3 times daily for 12 weeks. The follow-up period was 24 weeks, and all groups received behavioral support. Data analyses were performed from May 3, 2023, to March 20, 2024.
Interventions
Cytisinicline, 3 mg, 3 times daily for 12 weeks; cytisinicline, 3 mg, 3 times daily for 6 weeks followed by placebo for 6 weeks; or placebo 3 times daily for 12 weeks. Main Outcomes and Measures Biochemically verified (carbon monoxide <10 ppm) continuous smoking abstinence during the last 4 weeks of 6- and 12-week treatments (primary outcome) and from end of treatment to 24 weeks (secondary outcome); Questionnaire of Smoking Urges; incidence of adverse events.
Results
Of 792 participants randomized (mean [SD] age, 52.0 [11.8] years; 439 [55.4%] female; mean [SD] cigarettes/d, 20.4 [7.5]), 628 (79.3%) completed the trial. Primary and secondary outcomes were significantly higher for both cytisinicline groups vs placebo. For 6-week treatment, 39 cytisinicline participants (14.8%) vs 16 placebo participants (6.0%) were abstinent during weeks 3 to 6 (odds ratio [OR], 2.9; 95% CI, 1.5-5.6; P < .001). For 12-week treatment, 80 cytisinicline participants (30.3%) vs 25 placebo participants (9.4%) were abstinent during weeks 9 to 12 (OR, 4.4; 95% CI, 2.6-7.3; P < .001). Continuous abstinence rates for the 6-week treatment were 6.8% (cytisinicline) vs 1.1% (placebo) from weeks 3 to 24 . Continuous abstinence rates for the 12-week treatment were 20.5% (cytisinicline) vs 4.2% (placebo) for weeks 9 to 24. Reduction in craving at week 6 was greater for cytisinicline than placebo (−15.2 points [95% CI, −16.4 to −14.0] vs −12.0 points [95% CI, −13.5 to −10.5]; P < .001). Cytisinicline was well tolerated with no treatment-related serious adverse events. Conclusions and Relevance The findings of the ORCA phase 3 trial reaffirms the efficacy and tolerability of cytisinicline at both 6- and 12-week treatment for smoking cessation, with benefits extending through 24 weeks. As a mechanism of effect, cytisinicline mitigated nicotine craving. Trial Registration ClinicalTrials.gov Identifier: NCT05206370
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
- Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California San Francisco.
- Department of Medicine and Stanford Prevention and Research Center, Stanford University, Stanford, California.
- Achieve Life Sciences, Seattle, Washington.
- Trial Architecture Consulting, Chevy Chase, Maryland.
Zitieren
APA
Rigotti, N. A., Benowitz, N. L., Prochaska, J. J., Rubinstein, M., Clarke, A., Blumenstein, B., Cain, D. F., & Jacobs, C. (2025). Cytisinicline for Smoking Cessation. JAMA Internal Medicine, 185(6), 648. https://doi.org/10.1001/jamainternmed.2025.0628
Vancouver
Rigotti NA, Benowitz NL, Prochaska JJ, Rubinstein M, Clarke A, Blumenstein B, et al. Cytisinicline for Smoking Cessation. JAMA Internal Medicine. 2025;185(6):648. doi:10.1001/jamainternmed.2025.0628
BibTeX
@article{Rigotti2025,
author = {Rigotti, Nancy A and Benowitz, Neal L and Prochaska, Judith J and Rubinstein, Mark and Clarke, Anthony and Blumenstein, Brent and Cain, Daniel F and Jacobs, Cindy},
title = {Cytisinicline for Smoking Cessation},
journal = {JAMA Internal Medicine},
year = {2025},
volume = {185},
number = {6},
pages = {648},
doi = {10.1001/jamainternmed.2025.0628}
}
EUVIMED